Difference between revisions of "Cabazitaxel (Jevtana)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 18: | Line 18: | ||
*9/14/2017: Approved at a lower dose (20 mg/m<sup>2</sup> every 3 weeks) in combination with [[Prednisone (Sterapred) | prednisone]] for the treatment of patients with metastatic castration-resistant [[prostate cancer]] previously treated with a [[Regimen_classes#Docetaxel-containing_regimen| docetaxel-containing treatment regimen]]. ''(Based on PROSELICA)'' | *9/14/2017: Approved at a lower dose (20 mg/m<sup>2</sup> every 3 weeks) in combination with [[Prednisone (Sterapred) | prednisone]] for the treatment of patients with metastatic castration-resistant [[prostate cancer]] previously treated with a [[Regimen_classes#Docetaxel-containing_regimen| docetaxel-containing treatment regimen]]. ''(Based on PROSELICA)'' | ||
*12/18/2020: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant [[prostate cancer]] previously treated with a [[Regimen_classes#Docetaxel-containing_regimen| docetaxel-containing treatment regimen]]. ''(Based on CARD)'' | *12/18/2020: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant [[prostate cancer]] previously treated with a [[Regimen_classes#Docetaxel-containing_regimen| docetaxel-containing treatment regimen]]. ''(Based on CARD)'' | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *3/17/2011: Initial marketing authorization as Jevtana. | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' XRP6258, TXD258, RPR116258A | *'''Code names:''' XRP6258, TXD258, RPR116258A | ||
| − | *'''Brand | + | *'''Brand names:''' Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel |
==References== | ==References== | ||
| Line 33: | Line 36: | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:EMA approved in 2011]] | ||
[[Category:FDA approved in 2010]] | [[Category:FDA approved in 2010]] | ||
Revision as of 16:46, 4 December 2021
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabazitaxel (Jevtana) package insert[1]
- Cabazitaxel (Jevtana) patient drug information (Chemocare)[4]
- Cabazitaxel (Jevtana) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/17/2010: Initial approval in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on TROPIC)
- 9/14/2017: Approved at a lower dose (20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on PROSELICA)
- 12/18/2020: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on CARD)
History of changes in EMA indication
- 3/17/2011: Initial marketing authorization as Jevtana.
Also known as
- Code names: XRP6258, TXD258, RPR116258A
- Brand names: Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel